Group One Trading’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$95K Sell
4,400
-800
-15% -$17.3K ﹤0.01% 4784
2025
Q4
$124K Sell
5,200
-6,300
-55% -$129K ﹤0.01% 4818
2025
Q3
$156K Sell
11,500
-1,800
-14% -$18.7K ﹤0.01% 4933
2025
Q2
$108K Buy
13,300
+2,000
+18% +$17.1K ﹤0.01% 4896
2025
Q1
$88.7K Buy
11,300
+10,100
+842% +$117K ﹤0.01% 4684
2024
Q4
$17.9K Buy
1,200
+300
+33% +$4.9K ﹤0.01% 5765
2024
Q3
$13.8K Buy
+900
New +$14.2K ﹤0.01% 5444
2024
Q2
Sell
-5,800
Closed -$110K 7353
2024
Q1
$110K Sell
5,800
-46,800
-89% -$809K ﹤0.01% 4079
2023
Q4
$1M Sell
52,600
-49,100
-48% -$785K ﹤0.01% 2461
2023
Q3
$1.83M Sell
101,700
-78,800
-44% -$1.58M 0.01% 1704
2023
Q2
$3.67M Buy
180,500
+180,400
+180,400% +$3.44M 0.01% 1204
2023
Q1
$1.82K Sell
100
-40,400
-100% -$772K ﹤0.01% 6634
2022
Q4
$838K Buy
+40,500
New +$1.11M ﹤0.01% 2588
2022
Q3
Sell
-150,300
Closed -$3.81M 8107
2022
Q2
$3.81M Buy
150,300
+146,400
+3,754% +$3.59M 0.01% 1502
2022
Q1
$123K Buy
3,900
+2,500
+179% +$83.8K ﹤0.01% 5296
2021
Q4
$57K Buy
1,400
+500
+56% +$19.4K ﹤0.01% 6225
2021
Q3
$31K Buy
+900
New +$28K ﹤0.01% 6901

Other funds holding RCUS

Group One Trading's RCUS Position: Q4 2025 in Review

Group One Trading sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 130,449 shares — an estimated $2.66M sold.

Group One Trading first reported a position in RCUS in Q4 2020 and held it in 14 quarters. The position peaked at $2.42M in Q3 2024. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Group One Trading reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 130,449 Arcus Biosciences shares in Q4 2025, an estimated $2.66M.
  • Group One Trading first reported a position in Arcus Biosciences in Q4 2020 and held it in 14 quarters.
  • Group One Trading's Arcus Biosciences position peaked at $2.42M in Q3 2024.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.